Medical Oncology

CAR-T

Questions discussed in this category

What is your approach to determining fitness for patients to undergo CAR-T therapy for relapsed/refractory multiple myeloma, and any absolute perceived contraindications for CAR-T?

1 Answer available

How do you incorporate radiation therapy in patients undergoing CAR T-cell therapy for DLBCL?

3 Answers available

With the recent ODAC review of the commerically available CAR-T therapies in relapsed/refractory myeloma post 1-3 lines of therapy, what is your preferred regimen/therapy for first relapse, and which are the situations where you would absolutely consider CAR-T therapy at first relpase?

1 Answer available

Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?

1 Answer available

How would you manage relapsed DLBCL in a patient who received second line CD19 CART treatment?

1 Answer available

Is there an optimal salvage radiation dose for relapsed post-CART disease?

1 Answer available

Would you offer bridging radiation before or after leukapheresis?

Are you concerned about cases where radiation has to be started urgently before leukapheresis?

1 Answer available

How soon after CAR T-cell therapy can salvage radiation be delivered?

3 Answers available

What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?

2 Answers available

How are you deciding between available third line therapies for post-transplant relapsed DLBCL?

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

2 Answers available

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

2 Answers available

Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?

2 Answers available

How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?

1 Answer available

How would you approach BCMA-directed therapy in a patient with myeloma and renal failure on dialysis?

Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion?

2 Answers available

How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?

How is this entity distinct from other secondary HLH entities?

2 Answers available

Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?

3 Answers available

How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?

How do you choose between CAR-T and autoSCT, for example?

3 Answers available

How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

1 Answer available

Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?

2 Answers available

What is the best approach for patients with DLBCL with early relapse (< 6 months) after initially attaining a CR with 6 cycles RCHOP?

Does this differ for a patient who had a longer remission before relapse?

4 Answers available

How do you incorporate CAR-T cell therapy for DLBCL in transplant-eligible patients?

Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...

4 Answers available

What is your treatment of choice for triple class refractory multiple myeloma?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

2 Answers available

How do you determine when to give a second CAR-T cell infusion to a pediatric or young adult patient with relapsed/refractory ALL?

2 Answers available

Do you offer fertility preservation to patients prior to CAR-T therapy?

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?

1 Answer available

Papers discussed in this category

N Engl J Med, 2021 Dec 11

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Lancet,

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

Blood, 2020 Sep 23

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.

International journal of radiation oncology, biology, physics, 2019-12-01

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.

The Lancet. Oncology, 2019-01

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Cancer immunology research, 2019-07

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Br J Haematol, 2020 Mar 5

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

Lancet, 2020 Sep 01

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Blood Adv,

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.

Int J Radiat Oncol Biol Phys, 2020 May 22

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.

The New England journal of medicine, 2017-12-28

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Radiother Oncol, 2021 Dec 7

Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?

Int J Radiat Oncol Biol Phys, 2021 Dec 1

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.

Int J Radiat Oncol Biol Phys, 2022 Dec 20

Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.

Transplant Cell Ther, 2022 Dec 30

Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.

Blood advances, 2020 Jul 28

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26

Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.

Blood advances, 2020 Nov 24

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Haematologica, 2023 Jun 15

Consolidative radiotherapy for residual FDG activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.

N Engl J Med, 2022 Dec 11

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

J Clin Oncol, 2022 Dec 22

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Blood Adv, 2022 May 10

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.

Blood, 2022 Dec 15

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.

Proc Natl Acad Sci U S A, 2019 Apr 15

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.

N Engl J Med,

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Blood, 2022 Mar 03

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

Lancet, 2021 Jun 24

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med, 2023 Feb 10

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

Lancet Oncol, 2021 Dec 03

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

Lancet, 2021 Jun 04

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.

Experimental hematology & oncology, 2022 Feb 28

Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.

J Hematol Oncol, 2022 Mar 26

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.

Blood advances, 2022 May 10

Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.

Transplant Cell Ther, 2023 Mar 17

Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.

The New England journal of medicine, 2024 Jun 01

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine, 2024 Jun 02

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 24

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Blood advances, 2023 Aug 22

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.

Related Topics in Medical Oncology